On August 22, 2019 Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, reported that clinical data highlighting real-world performance of the Company’s Target Selector platform for detecting actionable biomarkers in lung cancer patients will be presented at the 2019 IASLC World Conference on Lung Cancer being held September 7-10, 2019 at the Fira Gran Via Exhibition and Conference Center in Barcelona, Spain (Press release, Biocept, AUG 22, 2019, View Source [SID1234538951]). The poster features clinical experience data from over 1,400 blood samples drawn from patients diagnosed with non-small cell lung cancer (NSCLC) and collected and shipped using Biocept’s CEE-Sure specimen collection tubes, specifically designed for liquid biopsy testing. Abstracts for posters to be presented at this conference can be found at library.iaslc.org.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster presentation details are as follows:
Title: The Dynamic Range of Mutant Allele Fraction Detected in Patients with NSCLC: Clinical Experience Data and Clinical Implications
Session Category/Title: P1.14/Targeted Therapy Session
Session Date and Time: Sunday September 8, 2019, 09:45am-18:00pm (CEST)
Location: Fira Gran Via Conference Center, Exhibit Hall, Poster Session P1.14
"To date, our clinical experience has demonstrated consistent performance for detecting actionable mutations in the ctDNA of patients with NSCLC as low as 0.01% mutant allele frequency," said Biocept’s Senior Vice President and Senior Medical Director Veena Singh, MD. "The ability to detect mutations at such low levels can serve to expand the cohort of patients that could potentially benefit from the use of targeted therapies and to monitor their progression or therapeutic response, as these patients might be missed with less sensitive technologies. We are also pleased to demonstrate the robust performance of our CEE-Sure blood collection tubes which are designed to stabilize cells in a given blood sample to minimize the presence of non-tumor DNA in the plasma fraction. We believe that our collection tube technology can contribute to a higher level of sensitivity in liquid biopsy testing."
"We are very pleased to highlight the robust real-world performance of our Target Selector ctDNA assays for lung cancer, as well as the utility of our CEE-Sure blood collection tubes at this year’s World Conference on Lung Cancer," said Biocept’s President and CEO Michael Nall. "We believe that these results add to the body of evidence supporting the clinical benefits of our proprietary molecular diagnostic technologies and services, and further distinguish our novel platform in the growing liquid biopsy segment."